Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06173518 | A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) | PHASE1 | RECRUITING | 30 | — | — | Nov 16, 2023 | Nov 1, 2027 | Mar 2, 2026 | 8 | United States, Spain +1 |
| NCT04404660 | A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) | PHASE1 | ACTIVE NOT_RECRUITING | 153 | — | — | Jun 3, 2020 | Jun 30, 2029 | Apr 8, 2026 | 34 | United States, Spain +1 |
| Arm | Type | Description |
|---|---|---|
| AUTO1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| AUTO1 | BIOLOGICAL | Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with anti-CD19 chimeric antigen receptor (CAR) T cells |
INCLUSION CRITERIA: * \< 18 years old at screening * ≥ 6 kg body weight at screening Pediatric patients with r/r B ALL r/r CD19-positive aggressive mature B including the B NHL subtypes: i) diffuse large B cell lymphoma, ii) Burkitt's lymphoma, iii) primary mediastinal large B cell lymphoma, iv) ...